Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
This article was originally published in The Tan Sheet
Executive Summary
FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities. Janet Woodcock is left scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.
You may also be interested in...
CDER Taps Genzyme Exec As Deputy Director For Science Operations
Richard Moscicki will fill new position that will help oversee center operations and provide “executive direction,” joining fellow deputy directors Robert Temple and Douglas Throckmorton.
CDER's Generational Shift: Many New Reviewers With Little Experience
While the center for drugs has enjoyed an influx of new reviewers in the last few years, the hiring frenzy has resulted in a significant shift in CDER's makeup: 38% of reviewers in the Office of New Drugs have less than two years of on-the-job experience. Office of New Drugs director John Jenkins discusses the challenges with training the new recruits, and how industry should adapt
Reinforcements At Last: CDER Hiring Process Well Underway
FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.